skip to Main Content
  • All
  • Other news
  • Corporate Information
Gubra People
Gubra and Boehringer Ingelheim sign 4th partnership, expanding their successful obesity treatment discovery collaboration

Today, Gubra announces the signing of a new research and license agreement with Boehringer Ingelheim to discover novel peptides for the treatment of obesity. The new research collaboration builds on…

GAN DIO-MASH model is top-ranked by the LITMUS consortium

Gubra’s GAN DIO-MASH mouse model has been top-ranked by the LITMUS¹ consortium for its human proximity score. The LITMUS consortium has evaluated a wide variety of preclinical MASH models using two…

news_GUBamy_A7S02923_1
Gubra announces first subject dosed in Phase 1 clinical trial of amylin agonist (GUBamy) for the treatment of obesity

Today, Gubra announces that the first human subject has been dosed with a new long-acting amylin agonist (GUBamy) as a potential treatment for obesity. This first clinical trial is a…

PPT_muusfoto_A50A9898
Trading statement Q3-2023: Continued strong performance

Today, Gubra released its trading statement for the third quarter of 2023. Organic revenue grew by 44% year-over-year in Q3-2023 (9M: 28%) for the CRO business with an adjusted EBIT-margin…

2023-08_CEO_thumb
Trading statement Q3-2023: CEO video statement

Today we publish our Q3 trading statement focusing closely on the performance of the company during the third quarter of 2023. Watch this video with CEO of Gubra Henrik Blou…

news_board3
Gubra strengthens Board of Directors

Gubra, a leader in preclinical services within metabolic and fibrotic diseases and with a strong pipeline of novel discovery projects, today announced the election of Monika Lessl and Astrid Haug…

Gubra – Extraordinary general meeting

Today, at 10:00 CET, Gubra A/S (“Gubra”) held an extraordinary general meeting at Plesner Advokatpartnerselskab, Amerika Plads 37, DK-2100 Copenhagen. All proposals presented to the general meeting were adopted:Item 1Election of…

Gubra enters into a Market Maker Agreement

Gubra announces hereby that is has entered into a Market Maker Agreement with Sydbank A/S to act as liquidity provider on Gubra shares. The agreement is effective as of 26…

Gubra raises financial guidance for full-year 2023

Today, Gubra announces preliminary Q3 and 9M 2023 results for the CRO business and revises its revenue and EBIT outlook for 2023 upwards, driven by strong performance in Q3 2023…

Tower Gubra_032723_1
Gubra opens its first US office in Boston

Gubra announces that it is opening its first US office on Kendall Square in Boston, the epicenter for the pharma and biotech community on the US East Coast. With more…

NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING

GUBRA A/S CVR NO. 30 51 40 41 To the shareholders of Gubra A/S (CVR no. 30 51 40 41), the board of directors hereby convenes an extraordinary general meeting…

Gubra submits clinical trial application (CTA) for first-in-human amylin trial

Gubra announces that a clinical trial application (CTA) for the anti-obesity amylin project has been submitted to the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. The clinical…

Completion of share buy-back programme

On 28 August 2023, Gubra A/S (“Gubra” or the “Company”) announced resumption of its share buy-back programme of in total 27,271 shares. The purpose of the share buy-back programme is…

Gubra resumes its share buy-back programme to hedge incentive scheme obligations

Gubra A/S (“Gubra” or the “Company”) today announces the resumption of its share buy-back programme, pursuant to which the Company intends to buy back up to 27,231 of its own…

financial_report_h12023
Interim report H1-2023: Strong performance and ahead of expectations

Today, Gubra released its interim report for the first half of 2023. Organic revenue grew by 21% year-over-year for the CRO business with an adjusted EBIT-margin of 27%. FY-2023 outlook…

ceo_statement_thumbnail
H1-2023 financial report. CEO Statement video.

Today we publish our interim report focusing closely on the performance of the company the first six months of 2023. Watch this video with CEO of Gubra Henrik Blou where…

logo_pressrelease
Gubra announces termination of collaboration with Bayer

Gubra and Bayer started the collaboration in 2021 Gubra will actively (alone or with a new partner) continue further development of the cardio-renal metabolic peptide programme Gubra sees great potential…

Gubra A/S announces signing of collaboration agreement with Hemab ApS

Today, Gubra announces the signing of an agreement with Hemab concerning a peptide collaboration. Under the terms of this pre-collaboration agreement, Gubra will start working on identifying peptide modulators suitable…

Gubra raises financial guidance for full-year 2023

Today, Gubra announces preliminary Q2 and H1 2023 revenue figures for the CRO business and revises its revenue outlook for 2023 upwards, driven by strong performance in Q2 2023 as…

logo_pressrelease
Information on share buy-back programme

On 30 June, 2023, Gubra A/S (“Gubra” or the “Company”) announced that a share buy-back programme of approximately DKK 2.5 million and up to a maximum of 27,231 shares has…

logo_pressrelease
Gubra launches share buy-back programme to hedge incentive scheme obligations

Gubra A/S (“Gubra” or the “Company”) today announces the initiation of a share buy-back programme, pursuant to which the Company intends to buy back up to 27,231 of its own…

PPT_muusfoto_A50A8445
Gubra acquires research service provider MiniGut ApS

Today, Gubra announces the acquisition of the Danish minipig service provider MiniGut ApS. MiniGut ApS is a fully equipped minipig contract research organisation (CRO) located at DTU Science Park in…

pipeline_web_image
Gubra announces updates to its pipeline. Internally developed brain-accessible orexin peptides for the treatment of narcolepsy, now ready for partnering

Gubra today announces updates to its R&D pipeline of internal and partnered projects. Most notably is the addition of a new CNS (orexin) peptide drug discovery project, now ready for…

logo_pressrelease
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…

logo_pressrelease
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…

Lise2
Discover Gubra’s hybrid business model

Watch our CEO Henrik Blou explain Gubra’s hybrid business model and how we operate in either of these two video presentations. One is in Danish, and one is in English. …

logo_pressrelease
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…

logo_pressrelease
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…

logo_pressrelease
Phase 1 trial results from a novel long acting NPY2-receptor agonist in partnership between Gubra A/S and Boehringer Ingelheim presented today at the European Congress on Obesity, ECO 2023

BI 1820237 a novel long-acting neuropeptide Y receptor type 2 (NPY2) agonist, has been evaluated in a phase 1 clinical trial. Results to be presented today at the ECO 2023…

logo_pressrelease
Gubra posts 19% CRO revenue growth in Q1 2023. Full-year 2023 outlook maintained.

Gubra, specialised in pre-clinical contract research services (CRO) and peptide-based drug discovery within metabolic and fibrotic diseases, today reported 19% revenue growth in the CRO business segment in Q1 2023…

logo_pressrelease
Invitation to the presentation of Gubra’s Q1-2023 results

Gubra will host a conference call for investors, analysts and media on Thursday, May 11, 2023, at 10:00am CET. The company's Q1-2023 Trading Statement will be published on the same…

logo_pressrelease
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…

logo_pressrelease
Partial exercise of the overallotment option in connection with the initial public offering of Gubra increasing total offering size to 4,913,521 shares

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…

logo_pressrelease
Gubra announces the end of the stabilisation period

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…

logo_pressrelease
Stabilisation measures taken

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…

logo_pressrelease
Major shareholder announcement

Gubra A/S, CVR no. 30514041 (the “Company” or “Gubra”) hereby announces that it has received a major shareholders' announcement pursuant to section 38 of the Danish Capital Markets Act regarding…

logo_pressrelease
Completion of the offering and registration of capital increase in Gubra A/S

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…

logo_pressrelease
No termination or withdrawal of Gubra A/S’ initial public offering

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…

logo_pressrelease
Major shareholder announcement

With reference to company announcements dated 20 March 2023 related to the publication of a prospectus for its initial public offering and listing of the shares of Gubra A/S, CVR…

logo_pressrelease
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…

logo_pressrelease
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…

logo_pressrelease
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…

logo_pressrelease
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…

nasdaq
Gubra publishes financial calendar for 2023

With reference to company announcement dated 20 March 2023 related to the publication of a prospectus for its initial public offering and listing of the shares of Gubra A/S (the…

logo_pressrelease
Stabilisation period begins

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…

logo_pressrelease
Gubra announces the result of its initial public offering

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…

logo_pressrelease
Gubra publishes prospectus and sets offer price at DKK 110 per share for its initial public offering and listing on Nasdaq Copenhagen

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…

logo_pressrelease
Gubra announces intention to launch an Initial Public Offering on Nasdaq Copenhagen and raise capital to support its growth strategy

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…

Screenshot-2023-02-19-025454
Collaboration with Ferring on Inflammatory Bowel Disease (IBD)

Saint Prex, Switzerland and Hørsholm, Denmark – November 15, 2022 Ferring Pharmaceuticals and Gubra entered into a collaboration agreement to further develop and characterize preclinical animal models of inflammatory bowel…

Vinder_Sjaelland_ENG-e1677076370639
Gubra once more awarded EY Entrepreneur Of The Year, Region Zealand.

Gubra once again wins the regional award title EY Entrepreneur of the year, Region Zealand In its justificatin, the EY committee recognizes Gubra’s development and enormous growth journey since our…

gubra_news_Gubra-strengthens-Board-of-Directors
Gubra strengthens Board of Directors with two international appointments

Hørsholm, Denmark – September 20, 2022 Gubra, a leader in preclinical services within metabolic and fibrotic diseases and with a strong pipeline of novel discovery projects, today announced the election…

muusfoto_IMG02886-scaled-1
Gubra reports record high revenue and earnings in 2021 and strengthens Board of Directors and Executive Management with new appointments

  Hørsholm, Denmark 23 May 2022 Gubra, a leader in preclinical services within metabolic and fibrotic diseases, and with a strong pipeline of novel discovery projects, today released its 2021…

Screenshot-2023-02-22-153437
Gubra ApS and Silence Therapeutics plc collaborate to develop RNAi therapies against novel liver-directed targets from Gubra’s streaMLine platform

HØRSHOLM, Denmark – 10 February, 2022 Gubra ApS announced today a new research collaboration with Silence Therapeutics PLC to develop novel RNAi therapeutics for liver diseases with an unmet medical…

NeuroPedia_link_1
Gubra launches NeuroPedia – a mouse brain atlas for virtual neuroscience

Hørsholm, Denmark, January 11 2022 Quantitative 3D imaging using light sheet fluorescent microscopy is revolutionizing the way we look at pre-clinical endpoints and biodistribution. The imaging team at Gubra are…

muusfoto_IMG_3393-scaled-1
Gubra and Bayer AG collaborate to develop next generation cardiorenal treatments

HØRSHOLM, Denmark – 20 September, 2021 Gubra ApS announced today a new research collaboration and license agreement with Bayer AG for the development of novel peptide therapeutics to treat cardiorenal disease.…

muusfoto_IMG08898-farve-scaled-1
Drug candidate from obesity collaboration between Gubra and Boehringer Ingelheim enters clinical phase 1 trial

HØRSHOLM, Denmark – 12 August, 2021 Recently, the first healthy volunteer was dosed with GUB002496 in a clinical phase 1 trial. GUB002496 is a drug candidate aiming for weight reduction.…

muusfoto_A50A0011-scaled
Annual results 2020: A thriving core business and razor-sharp biotech profile

Hørsholm, Denmark 28 May 2021 Gubra achieves strong growth results in its core CRO business. New models in the Kidney Space and in 3D imaging well received by the market.…

gubra_csr_Beplantning-Tullebolle-Lokkebyvej
Gubra wins sustainability prize 2020

We are so proud of winning this prize. Gubra wins the EY Entrepreneur of the Year Sustainability Prize 2020. The jury recognizes Gubra for our clear attitude in CSR and active…

Screenshot-2023-02-22-154341
Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity

Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity The research agreement builds upon the successful relationship between Boehringer Ingelheim and Gubra…

collage
Gubra wins EY Entrepreneur of the Year, Region Zealand 2020

Gubra is awarded EY Entrepreneur of the Year 2020, Region Zealand for the 2nd year in a row. The digital award ceremony took place 3rd December. The jury highlights “…the…

CSR-Report-2019_image
A call for simple and comparable CSR reporting

HØRSHOLM, Denmark – May 26, 2020 Gubra sets a new standard for simple and comparable CSR reporting. In the company’s first CSR Report for 2019, Gubra proves that it is…

Vi-cykler-til-arbejde-screenshot_september
A year of solid financial growth, scientific breakthroughs, and strong green commitment

Hørsholm, Denmark 15 May 2020 In 2019 Gubra maintains strong financial growth based on solid results in both the biotech business and the CRO business. Gross profit increases 40% to…

Vi-cykler-til-arbejde-screenshot_september
Gubra is sponsor of BIKE TO WORK

HØRSHOLM, Denmark – March 9, 2020 Gubra is sponsor of this year’s Danish bike campaign BIKE TO WORK BIKE TO WORK (VI CYKLER TIL ARBEJDE) is Denmark’s big national bike…

Screenshot-2023-02-22-154817
Co-financed industrial PhD scholarship from DDA

HØRSHOLM, Denmark – March 6, 2020 Congratulations to Gubra and PhD student Mathias Bonde Møllerhøj (MSc). We just received a co-financed industrial PhD scholarship from the Danish Diabetes Academy for…

collage-1
Gubra wins EY Entrepreneur of the Year

HØRSHOLM, Denmark – October 30, 2019 Tuesday evening at Ledreborg Castle took a sweeping turn upwards for Jacob Jelsing and Niels Vrang when they proudly stepped up at the podium to receive…

Screenshot-2023-02-22-154341
Gubra announces the nomination of a co-invented clinical candidate from first obesity collaboration with Boehringer Ingelheim

HØRSHOLM, Denmark – June 28, 2019 On September 7, 2017, Boehringer Ingelheim and Gubra announced a collaboration for the development of novel peptide compounds to treat obesity. In June 2019,…

Screenshot-2023-02-22-154341
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

INGELHEIM, Germany and HØRSHOLM, Denmark – May 29, 2019 Obesity is a complex disease and leading cause of morbidity and mortality and there are only insufficient treatment options available. New…

gubra_office
JDRF and Gubra join forces to develop a new glucose responsive insulin for diabetes

New York and Hørsholm, Denmark, 18 June 2018 JDRF and Gubra today announced a partnership to develop a glucose-responsive insulin (GRI) as a treatment for people with insulin-requiring diabetes, such…

muusfoto_A50A9188
Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments

INGELHEIM, Germany and HØRSHOLM, Denmark – September 7, 2017 Obesity affects more than half a billion people worldwide and is a leading risk factor for some of the biggest global…

gubra_csr_muusfoto_A50A5237
Gubra reaches third research milestone under a collaboration agreement with Sanofi

Hørsholm, August 30, 2017 Today, Gubra announced the successful conclusion of a research collaboration with Sanofi, focusing on the discovery of novel gastrointestinal peptides that could potentially lead to the…

muusfoto_IMG02886-scaled-1
Gubra announces changes to executive management team

June 1, 2016 Today, Gubra announced a change in its executive management team. In order to continue to stay focused on high scientific standards and to accommodate strong growth going…

Sanofi-Logo
Gubra announces research collaboration agreement with Sanofi to discover and develop peptide-based drugs targeting diabetes and obesity

Hørsholm, September 23, 2013 Gubra today announced the launch of a new research collaboration agreement with Sanofi focusing on the discovery of gut peptides in order to identify novel targets…

Subscribe for

Company updates

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top